Open AccessA preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
Author(s) -
К. К. Лактионов,
Д. И. Юдин,
V. Breder,
Е. В. Реутова,
К. П. Лактионов,
D Marinov,
Д. А. Перегудов,
М. С. Ардзинба
Publication year - 2019
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2019-10-110-114
Subject(s) - gefitinib , medicine , carboplatin , oncology , lung cancer , chemotherapy , clinical endpoint , pemetrexed , progression free survival , paclitaxel , epidermal growth factor receptor , randomized controlled trial , cancer , cisplatin
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles of paclitaxel 175 mg / m2 and carboplatin AUC5 were administrated at days 71-113. Thereafter, gefitinib was re-started on day 135 and continued until disease progression. The primary endpoint was progressive free survival (PFS) time. One-year PFS in all patients group included in the study at the time of the preliminary analysis was 79.8%, median PFS was 17 months (13.5–23, CI 95%). In the group of integrated chemotherapy one-year PFS was 89.3%, median PFS was 19 months (14–23.5, CI 95%).